TY - JOUR T1 - Effects of Nucleotide Analogs at the P2X3 Receptor and Its Mutants Identify the Agonist Binding Pouch JF - Molecular Pharmacology JO - Mol Pharmacol SP - 80 LP - 89 DO - 10.1124/mol.112.077818 VL - 82 IS - 1 AU - Thomas Riedel AU - Sara Wiese AU - Anna Leichsenring AU - Peter Illes Y1 - 2012/07/01 UR - http://molpharm.aspetjournals.org/content/82/1/80.abstract N2 - In this study, we investigated the effects of single alanine substitutions of amino acid residues in the supposed ATP binding site of the human P2X3 receptor on the agonistic effect of nucleotide analogs. The wild-type and mutant receptors were expressed in HEK293 cells, and the nucleotide effects were measured by means of the whole-cell patch-clamp method. Modifications in the receptor binding site changed the concentration-response relationship, the current kinetics, and the recovery from desensitization during fast, pulsed, local agonist applications. On the basis of this fact, we were able to distinguish binding from other effects, such as gating/desensitization, by using a hidden Markov model that describes the complete channel behavior with a matrix of rate constants. The binding energies of the nucleotide analogs were calculated and compared with the binding energies of ATP at both the wild-type receptor and its alanine mutants. Changes in the binding energies caused by alterations in the receptor and/or agonist structures were concluded to be attributable to the preferential binding of certain structural constituents of ATP to certain amino acid moieties of the receptor. The results were also checked for consistency with a P2X3 homology model that we developed from the known zebrafish P2X4 crystal structure in the closed state. The functional data correlated well with the predictions of the agonist dockings to the structural model. ER -